Theranovir
4 rue Pierre Fontaine
91058 EVRY Cedex – France
Email : contact@theranovir.com
Zakia BELAID-SANDAL : CEO
As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.
Discover >Genopole accompanies researchers, postdocs and start-up entrepreneurs through all the phases of their projects to ensure the best possible conditions for business development.
Discover >Every day, at Genopole, researchers, entrepreneurs and students cross paths, share ideas and unite forces in a veritable melting pot for innovation.
Discover >Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.
Discover >Biotechnology, R&D, Drug development, oncology, obesity, infectious diseases
BACKGROUND
Young and multidisciplinary French start-up, THERANOVIR develops immunotherapeutic innovative antibodies for three diversified and interconnected pathologies:
This project is the result of academic research
DESCRIPTION OF THE PRODUCTS / SERVICES / TECHNOLOGY
The main axe of THERANOVIR is oncology. THERANOVIR is developing innovative therapeutic monoclonal antibodies targeting both tumor cells (stem and non-stem) and cells of the microenvironment in combination with a companion immunohistological test. Being in the preclinical phases, candidates under development will be proposed in combination in response to therapeutic failures of checkpoint inhibitors and / or anti-angiogenesis in combination with chemotherapy.
At the same time, THERANOVIR is progressing in the development of immunotherapeutic antibodies targeting obesity.
COLLABORATIONS SOUGHT
THERANOVIR is currently looking for funding to progress in the preclinical development in order to enter the regulatory and the clinical phases.
We are interested to tie partnerships with big pharma to ensure the development of our products in clinical phases and beyond.
The IP is protected by a family of 2 patents covering Europe, US and Asia that THERANOVIR exploits via a global and exclusive license from INSERM Transfert.
STRENGTHS
Cohesive and complementary skilled team, 100% of employees are PhD holders. THERANOVIR is supported by an advisory board represented by KOL experts.
THERANOVIR is surrounded by an ecosystem supporting innovations and specially startup in Health-Tech represented by Genopole, Medicen, Mabdesign, France Biotech, Bpifrance, Region Ile-de-France.
INNOVATION ASSETS
The target is a new complex of proteins expressed in many cancer types which allows us to propose an agnostic therapy.
The offer is complete including companion test to identify if the treatment is effective on the patient and the therapy itself.
The therapy is validated in vitro and in vivo recently and until today, there is no treatment targeting this protein complex in the pharmacopeia.
In same field